Pharmaceutical Executive December 12, 2024
This acquisition will bring Aliada’s Alzheimer’s treatment under AbbVie’s pipeline.
AbbVie announced the completion of its acquisition of Aliada Therapeutics.1 As a result, Aliada’s lead investigational asset, ALIA-1758, is an Alzheimer’s treatment that’s in Phase 1 trials and will now fall under AbbVie’s pipeline.
In a press release, AbbVie vice president of neuroscience development Dawn Carlson, MD, MPH, said, “Alzheimer’s disease poses a significant public health challenge, impacting millions worldwide and is becoming more prevalent as populations age. With the acquisition now complete, we look forward to advancing potentially disease-modifying therapies such as ALIA-1758 for Alzheimer’s disease and bolstering our neuroscience discovery and development efforts by leveraging Aliada’s novel CNS drug delivery platform.”
AbbVie first announced its plans to acquire...
Today's Sponsors
Today's Sponsor